Prevalence of and risk factors for postoperative hemorrhage after lower third molar extraction on warfarin therapy: a multicenter retrospective study in Japan
- 3 Downloads
Postoperative hemorrhage after tooth extraction is a critical and clinically important issue for clinicians and patients receiving anticoagulants. The purpose of the present study was to investigate the prevalence of and risk factors for postoperative hemorrhage after lower third molar extraction in Japanese patients receiving warfarin therapy. A total of 142 patients who underwent lower third molar extraction between January 2010 and December 2016 were included, and their medical records were retrospectively reviewed. The prevalence of and risk factors for postoperative hemorrhage were investigated. The prevalence of postoperative hemorrhage after lower third molar extraction was significantly higher in patients receiving warfarin than in healthy subjects (21.8% vs 0.7%, P < 0.001). The cutoff value for PT-INR was 2.11 based on a receiver-operating characteristic analysis. A multivariate analysis indicated that an elevated PT-INR value [hazard ratio (HR) 3.798, 95% confidence interval (CI) 1.400–10.467, P < 0.01], preoperative antibiotic administration (HR 4.434, 95% CI 1.591–14.775, P < 0.01), difficulties with intraoperative hemostasis (HR 16.298, 95% CI 2.986–110.677, P < 0.01), and higher serum creatinine levels (HR 7.465, 95% CI 1.616–39.576, P < 0.05) are significant predictors of postoperative hemorrhage after lower third molar extraction. Multivariate correlations were observed between risk factors including an elevated PT-INR value, preoperative antibiotic administration, and higher serum creatinine levels, and postoperative hemorrhage after lower third molar extraction in patients receiving warfarin therapy. Clinicians need to consider these risk factors for postoperative hemorrhage after the lower third molar extraction and monitor PT-INR in patients receiving warfarin therapy.
KeywordsPostoperative hemorrhage Lower third molar Extraction Warfarin therapy Risk factor
SY and HK: conception and design of the study. SY and HK: analysis and interpretation of data. SY, TH, SS, HY, MM, NU, KO, SH, SR, HN, SF, MA, YK, TK, YS, MU: collection and assembly of data. SY: drafting of the article. SY: critical revision of the article for important intellectual content. HK: final approval of the article.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study protocol was approved by the Ethics Committee of the Shinshu University School of Medicine. (No3798).
For this type of study, formal consent is not required.
- 9.Iwabuchi H, Imai Y, Asanami S, Shirakawa M, Yamane GY, Ogiuchi H, Kurashina K, Miyata M, Nakao H, Imai H. Evaluation of postextraction bleeding incidence to compare patients receiving and not receiving warfarin therapy: a cross-sectional, multicentre, observational study. BMJ Open. 2014. https://doi.org/10.1136/bmjopen-2014-005777.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Hasegawa T, Yanamoto S, Tachibana A, Kojima Y, Koyama Y, Maeda M, Komori T, Japanese Study Group of Cooperative Dentistry with Medicine (JCDM). The risk factors associated with postoperative hemorrhage after tooth extraction: a multi-center retrospective study of patients receiving oral antithrombotic therapy. Oral Maxillofac Surg. 2017;21:397–404.CrossRefGoogle Scholar
- 16.Nakatani S, Mitsutake K, Hozumi T, Yoshikawa J, Akiyama M, Yoshida K, Ishizuka N, Nakamura K, Taniguchi Y, Yoshioka K, Kawazoe K, Akaishi M, Niwa K, Nakazawa M, Kitamura S, Miyatake K, Committee on Guideline for Prevention and Management of Infective Endocarditis, Japanese Circulation Society. Current characteristics of infective endocarditis in Japan: an analysis of 848 cases in 2000 and 2001. Circ J. 2003;67:901–5.CrossRefGoogle Scholar
- 17.Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817–21.CrossRefGoogle Scholar
- 29.Brodsky SV, Collins M, Park E, Rovin BH, Satoskar AA, Nadasdy G, Wu H, Bhatt U, Nadasdy T, Hebert LA. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010;115:c142–6.CrossRefGoogle Scholar
- 30.Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayer WC, Ma Z, Hemmelgarn BR, Alberta Kidney Disease Network. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015;350:h246.CrossRefGoogle Scholar
- 31.Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, Saposnik G, Sood MM, Molnar AO, Perl J, Wald RM, Silver S, Wald R. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol. 2017;33:737–46.CrossRefGoogle Scholar
- 32.Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K, Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke. 2008;39:1740–5.CrossRefGoogle Scholar
- 35.Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–55.CrossRefGoogle Scholar